DYAX. Dyax Corp. and Kadmon Sign Strategic Licensing Agreement for DX-2400 Novel MMP-14 Inhibitor to be Developed in Multi-Indication Oncology Program http://finance.yahoo.com/news/dyax-corp-kadmon-sign-strategic-113000340.html stockcharts.com/c-sc/sc?s=DYAX&p=W&yr=1&mn=0&dy=0&i=t09469027681&r=1348140786362